GHK-Cu is a naturally occurring tripeptide bound to copper, sold in serums and creams for skin firmness, wrinkles, and wound repair. Small topical cosmetic trials show modest, real effects on skin. The injectable form used by peptide hobbyists has essentially no human trial evidence — that route is unstudied and unregulated.
GHK-Cu sits at grade C; BPC-157 at grade D. On evidence alone, GHK-Cu is the safer recommendation. That said, "stronger evidence" doesn't always mean "right for you" — read both pages, then talk to a clinician.
Several small, often industry-funded RCTs of topical GHK-Cu creams report modest improvements in firmness, fine lines and hydration. Real effect, but small samples and conflicts of interest mean the size of the benefit is uncertain.
Mechanistic and animal evidence is consistent — accelerated repair, better-organised collagen. The prescription form (prezatide copper acetate / Iamin) was once developed for chronic wounds, but is not in current clinical use.
Marketed as a hair-loss ingredient. Strong cell-level rationale but very limited controlled human evidence specifically for GHK-Cu monotherapy.
Strong, repeated results in rodents. No published controlled human trials confirming the effect.
The most-studied area in animals; the peptide was first characterised for gastric protection.
Popular real-world use, but supported only by self-reports.
Topical GHK-Cu has a long cosmetic safety history and is generally well tolerated; mild irritation or contact reactions occur occasionally. Independent reviews by cosmetic safety panels have judged it safe for use in cosmetics at the concentrations used. The safety picture for injection is entirely different: there are no controlled human safety trials, products sold online are unregulated, and copper-containing solutions raise questions about long-term local and systemic accumulation that have not been formally answered. Caution is particularly warranted in pregnancy, breastfeeding, in people with Wilson's disease or other copper-handling disorders, and in anyone with active malignancy (some lab work suggests GHK alters cancer-relevant gene expression in directions that have not been clinically validated).
Because there are no large human studies, the side-effect profile in people is essentially unknown. Animal studies report relatively low toxicity, but that does not establish human safety, purity, or long-term risk. Products sold online are unregulated, so contamination and mislabelling are real concerns. People who are pregnant, breastfeeding, have cancer, or take other medicines should be especially cautious.
GHK-Cu sits at grade C; BPC-157 at grade D. On evidence alone, GHK-Cu is the safer recommendation. That said, "stronger evidence" doesn't always mean "right for you" — read both pages, then talk to a clinician.
Pepwyse comparison pages are generated from the same structured data behind each peptide profile. Want a different head-to-head? Use the compare picker or ask GHK-Cu directly via the Ask-Peppy button. Not medical advice — see how we grade evidence.